Pregnant women make decisions about medicines based on insufficient, incomplete, and randomly available information with varying quality. More than five million European women become pregnant every year. Most of them use at least one medicine during their pregnancy. A recent master thesis from the ConcePTION project shows that giving women easy access to information from sources they can trust can empower them to make decisions about medicines in pregnancy.
Women with chronic illnesses get pregnant, and women who are pregnant get ill. For every pregnancy, women and their doctors have to weigh the benefits against harms of anything from upset stomach with over-the-counter aspirin to get rid of a headache, to risking death or disability from stopping treatment for epilepsy. Most of these drugs have not been studied in pregnancy, which means that both women and their babies are potentially at risk.
“Studies on the use of drugs show that most women use medicines during pregnancy, with estimates ranging from 44-99%. Nevertheless, most medicines have not been adequately studied in pregnant women. As a consequence, these women, their partners, and their doctors take very difficult decisions based on insufficient evidence”, says Dr. David Lewis, Qualified Person for Pharmacovigilance at Novartis & Senior Visiting Research Fellow, University of Hertfordshire, who leads work to develop a ConcePTION app for patient or health professional reporting of medication use in pregnancy, and providing evidence-based information.
But how can, and how do, women access reliable information? Amalia Alexe (pictured above) recently defended her master thesis “Is my treatment harming my baby?”, where she analysed public health information from the patient’s perspective. The aim was to understand how patients can make informed choices about medicines and their use during pregnancy. The work builds on a patient survey to explore views and opinions about publicly available information of the use of medicines in pregnancy.
Her work indicates that women will be empowered by having easy access to trusted information sources through a mobile app. She is part of the team that is developing an app where women, healthcare professionals and manufacturers can report pregnancy exposures. Based on her preliminary research, she anticipates that the app will encourage women to contribute to improving the information sources that already exist by sharing information about drugs they have taken during pregnancy. The app will also support women being able to contribute to better understanding the safety of medicine use when breastfeeding by asking if women would consider donating breast milk samples to the ConcePTION biobank for analysis and assessment.
“Women will have the opportunity to participate in long-term pregnancy studies through continuous access to information on their child’s health and development via the app. By participating in the ConcePTION project through use of the App, women will also help future mothers to make well-informed health decisions for themselves, and for their children” says Amalia Alexe, EU2P Master of Science student, PV Operational and Compliance Lead, Advanced Accelerator Applications, and co-leader of the team that is developing the ConcePTION app for information sharing and reporting.
By Josepine Fernow